EKF Diagnostics business update

Wednesday, Dec 15 2010 by
2

EKF Diagnostics, the Point of Care (PoC) diagnostics company, held a meeting in London to update analysts on business progress and the recent acquisition of Argutus Medical.

EKF Diagnostics CEO Julian Baines and FD Paul Foulger reported that the business is progressing well, having completed three acquisitions in roughly six months (EKF Diagnostics GmbH, Quotient Diagnostics and Argutus). The German based EKF business is operating profitably, and the team has won significant sales contracts in Peru and Mexico with the company's flagship Hemo-Control system. EKF is currently negotiating new distributor relationships for the promising US market (for which it is already approved and CLIA waived).

EKF completed the acquisition of Quotient Diagnostics in October, and is expanding the marketing of its PoC HbA1c testing system for diabetes (QuoTest). QuoTest is important in EKF's strategy because it is a quick, cheap and fast test - appropriate for use in a clinic or doctor's office and central to the growth strategy. QuoTest is approved for sale in Europe and China (cartridge approval pending), and a lower cost version (QuoLab) will be launched in Q3 2011.

EKF recently acquired Dublin based Argutus Medical for £2.2 million in shares. The primary reason for the acquisition is to gain access to Argutus' acute kidney injury (AKI) biomarkers. The AKI market is worth $ 1 billion + globally and has applications in diabetes and sepsis, as well as post-operative applications in coronary bypass and organ transplantation. EKF plans to develop PoC assays using the Argutus biomarkers - ultimatley developing an AKI diagnostic that works in a matter of minutes rather than the 2-3 days that current tests require. Argutus CEO Cormac Kilty will join EKF as Chief Technical Officer - filling the need for a technical expert at the group management level.


Disclaimer:  

This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.


Do you like this Post?
Yes
No
2 thumbs up
0 thumbs down
Share this post with friends



EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The Company's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240. more »

LSE Price
14.88p
Change
 
Mkt Cap (£m)
69.1
P/E (fwd)
37.4
Yield (fwd)
n/a



  Is EKF Diagnostics Holdings fundamentally strong or weak? Find out More »


What's your view on this thread? Log In to Comment Now

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder